Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.50 |
| ▸ | KIF11 | P52732 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.42 |
| ▸ | HTR3B | O95264 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23886329 | 0.98 | ACHE (0.48) | ACHEKIF11CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7694753 | 0.86 | ACHE (0.50) | ACHEKIF11CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2247542 | 0.85 | ACHE (0.55) | ACHEKIF11CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2138732 | 0.85 | ESR1 (0.44) | KIF11CYP2C19ALDH1A1MAPK1TAAR1 | |
| Hydrochloric Acid SCHEMBL18894298 | 0.82 | ESR1 (0.43) | KIF11CYP2C19MAPK1TAAR1IDO1 | |
| SCHEMBL16231401 | 0.82 | ACHE (0.46) | ACHEKIF11CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29714909 | 0.80 | ACHE (0.55) | ACHEKIF11CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL348758 | 0.80 | ACHE (0.55) | ACHEKIF11CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8784697 | 0.80 | ACHE (0.55) | ACHEKIF11CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10409637 | 0.80 | ACHE (0.55) | ACHEKIF11CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024042316-A1 | PYRIDO-PYRAZOLES AS INHIBITORS OF DDR'S FOR THE TREATMENT OF FIBROTIC DISORDERS AND CANCER | REDX PHARMA PLC. (GB) | 2024-02-29 | — | — | WO | disclosed |
| EP-4326257-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023079291-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA PLC (GB) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023021278-A1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | REDX PHARMA PLC (GB) | 2023-02-23 | — | — | WO | disclosed |
| US-20220348568-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | INC., CHEMOCENTRYX | 2022-11-03 | — | — | US | disclosed |
| WO-2022225832-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2022-05-26 | — | — | US | disclosed |
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
| WO-2020182666-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2020-09-17 | — | — | WO | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
| US-7214715-B2 | Compounds to treat Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060106256-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2006-05-18 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | disclosed |
| US-6200993-B1 | ASTHMA; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-03-13 | — | — | US | disclosed |
| US-4627874-A | RICE PRODUCTION | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1986-12-09 | — | — | US | disclosed |
| US-4455164-A | HALOGENATED DERIVATIVES | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1984-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348568-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | CXCR1, CXCR5, CXCR6 | ACHE 3767/4885KIF11 3253/4885CYP3A4 2802/4885 |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | ACHE 2966/4885KIF11 3835/4885CYP3A4 1703/4885 |
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | ACHE 813/4885KIF11 4281/4885CYP3A4 518/4885 |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | ACHE 7/4885KIF11 2242/4885CYP3A4 1415/4885 |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | ACHE 5/4885KIF11 1712/4885CYP3A4 1901/4885 |
| US-20060106256-A1 | Substituted hydroxyethylamines | HNMT, PNMT, BCHE | ACHE 62/4885KIF11 3984/4885CYP3A4 459/4885 |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | ACHE 2179/4885KIF11 4468/4885CYP3A4 319/4885 |
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL15, IL2 | ACHE 4837/4885KIF11 2769/4885CYP3A4 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.